tetano
Editor, Senior Moderator
J Innate Immun. 2018 Jun 1:1-7. doi: 10.1159/000489405. [Epub ahead of print]
[h=1]Mucosal Immune Response in Nasal-Associated Lymphoid Tissue upon Intranasal Administration by Adjuvants.[/h] Takaki H[SUP]1,[/SUP][SUP]2[/SUP], Ichimiya S[SUP]2[/SUP], Matsumoto M[SUP]1[/SUP], Seya T[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The nasal administration of vaccines directed against diseases caused by upper respiratory tract infections of pathogens, such as the influenza virus, mimics the natural infection of pathogens and induces immunoglobulin A (IgA) production in the nasal cavity to effectively protect viral entry. Therefore, the development of a nasally administered vaccine is a research objective. Because the antigenicity of influenza split vaccines is low, nasal inoculation with the vaccine alone does not induce strong IgA production in the nasal cavity. However, the addition of adjuvants activates the innate immune response, enhancing antigen-specific IgA production and the T-cell response. Although the development of suitable adjuvants for nasal vaccinations is in progress, the mechanism by which adjuvants promote the immune response is still unclear. In this review, we discuss the mucosal immune response, especially in the nasal-associated lymphoid tissue, induced in response to the intranasal inoculation of an influenza vaccine and adjuvants in animal models.
[h=4]KEYWORDS:[/h] Immunoglobulin A; Influenza vaccine; Mucosal immunity; Nasal-associated lymphoid tissue
PMID: 29860261 DOI: 10.1159/000489405
[h=1]Mucosal Immune Response in Nasal-Associated Lymphoid Tissue upon Intranasal Administration by Adjuvants.[/h] Takaki H[SUP]1,[/SUP][SUP]2[/SUP], Ichimiya S[SUP]2[/SUP], Matsumoto M[SUP]1[/SUP], Seya T[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The nasal administration of vaccines directed against diseases caused by upper respiratory tract infections of pathogens, such as the influenza virus, mimics the natural infection of pathogens and induces immunoglobulin A (IgA) production in the nasal cavity to effectively protect viral entry. Therefore, the development of a nasally administered vaccine is a research objective. Because the antigenicity of influenza split vaccines is low, nasal inoculation with the vaccine alone does not induce strong IgA production in the nasal cavity. However, the addition of adjuvants activates the innate immune response, enhancing antigen-specific IgA production and the T-cell response. Although the development of suitable adjuvants for nasal vaccinations is in progress, the mechanism by which adjuvants promote the immune response is still unclear. In this review, we discuss the mucosal immune response, especially in the nasal-associated lymphoid tissue, induced in response to the intranasal inoculation of an influenza vaccine and adjuvants in animal models.
[h=4]KEYWORDS:[/h] Immunoglobulin A; Influenza vaccine; Mucosal immunity; Nasal-associated lymphoid tissue
PMID: 29860261 DOI: 10.1159/000489405